Introduction
Diabetes is associated with accelerated atherosclerosis, and type 2 diabetic patients in particular are at increased risk of cardiovascular events such as myocardial infarction and stroke. 1 Although many studies have shown a correlation between hyperglycaemia and cardiovascular disease, it remains unclear whether glycaemic control is an effective method to reduce the incidence or progression of macrovascular diseases in patients with type 2 diabetes. 2 Since atherosclerosis is a multifactorial disease, a greater inhibition of atherosclerosis may be obtained by glucose-lowering agents that have other effects specifically related to vascular disease.
The United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that metformin reduced macrovascular complications and mortality in type 2 diabetic patients. 3 Besides its glucoselowering effects, metformin appears to exert beneficial effects on several cardiovascular risk factors, including dyslipidaemia, plasminogen activator inhibitor 1, C-reactive protein, fibrinogen, insulin resistance, and hyperinsulinaemia. [4] [5] [6] [7] [8] Metformin may also decrease oxidative stress. 9, 10 Despite its apparent intrinsic vasculoprotective properties, 11, 12 the mechanisms of action of metformin in the vascular wall are unclear. One of the key initial events in atherogenesis is the adhesion of monocytes to the endothelium. Monocyte binding to endothelium is enhanced in patients with diabetes. 13, 14 The factors contributing to this alteration are poorly understood but may involve hyperglycaemia and advanced glycation end-products (AGE). [15] [16] [17] In the present study, we evaluated the effect of metformin on AGE-induced monocyte adhesion to endothelium. We also investigated the effect of metformin on monocyte differentiation into macrophages and foam cell formation, the hallmarks of early atherosclerosis.
Research design and methods Reagents
Endothelial cell basal medium (EBM) and endothelial cell growth medium (EGM) were purchased from Clonetics (San Diego, CA). Dianisidine dihydrochloride, hexadecyltrimethylamine ammonium bromide (HTAB), oil red O, lipopolysaccharide (LPS), o-Phenylnediamine dihydrochloride (OPD), and monoclonal anti-beta-actin (mouse IgG1 isotype) were purchased from Sigma (St Louis, MO). Penicillin-streptomycin, TRizol reagent, phosphatebuffered saline (PBS), Hanks Balanced Salt Solution (HBSS), and RPMI 1640 medium were obtained from GIBCO (Grand Island, NY). Foetal bovine serum (FBS) and trypsin/ethylenediamine tetra-acetic acid (EDTA) were obtained from Wisent (St Bruno, Quebec, Canada). Monoclonal antibody to scavenger receptor type A (SR-A) was purchased from Serotech (Raleigh, NC). Lectin-like oxidised low-density lipoprotein (LDL) receptor-1 (LOX-1) affinity-purified polyclonal antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Endothelial cell culture
Human umbilical vein endothelial cells (HUVECs) and human aortic endothelial cells (HAECs) were obtained from Clonetics (San Diego, CA). They were grown to sub-confluence in EGM at 37°C in 5% CO 2 /95% air atmosphere. The cells were then trypsinised and sub-cultured in 24-well culture plates. All treatments were carried out in serum-free EBM.
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Isolation of human monocytes
Human monocytes were isolated from fresh heparinised blood (100 ml) collected from non-smoker healthy male and female donors as previously described. 18 First, peripheral blood mononuclear cells were obtained by density centrifugation using Lymphoprep (Nycomed Pharma As, Oslo, Norway). The cells collected from the interface were washed three times with HBSS, and allowed to aggregate in the presence of FBS. After further purification by the rosetting technique and density centrifugation, recovery of highly purified monocytes (85-90%), as assessed by fluorescence-activated cell sorter analysis, was obtained. Human monocytes were resuspended in serum-free RPMI 1640 medium supplemented with 100 lU/ml penicillin-streptomycin. In some experiments, monocytes were differentiated into macrophages by culturing the cells for nine days at 37°C in the presence of 10% autologous serum.
Monocyte adhesion assay
On the day of the assay, the medium of confluent endothelial cells (ECs) was gently removed and the cells were washed twice with HBSS. 2.3 x 10 5 highly purified human monocytes were then added to the wells and allowed to adhere to ECs for 2 hours. At the end of this incubation period, non-adherent monocytes were removed by washing the cells with PBS (pH 6.0). Monocyte adhesion to ECs was quantitated by measuring monocyte myeloperoxidase (MPO) activity as previously described. 19 Isolation of human LDL LDL was isolated from plasma obtained from healthy non-smoker normolipidaemic male and female donors. Venous blood was collected into tubes containing EDTA and LDL (density = 1.019 to 1.063) was isolated by sequential ultracentrifugation using potassium bromide (KBr) for density adjustments. LDL was sterilised by filtration through 0.20 µm Gelman filters. Minimally modified LDL (MM-LDL) was obtained by storage of EDTA-free LDL at 4°C for at least three months. Protein content of LDL preparations was determined using the Bradford method 20 with bovine serum albumin (BSA) as standard. Endotoxin content of LDL preparations (100 µg/ml) was determined by the Limulus amebocyte lysate assay (Sigma Chemical Co) and was consistently found to be lower than 3 pg/ml.
Preparation of AGEs
Immunoglobulin free BSA (Sigma) was subjected to non-enzymatic glycation by incubation with glucose 0.5 mol/L in 0.4 mol/L PBS containing 0.5 mmol/L EDTA. The solution was sterile-filtered by passage through a 0.2 µm Gelman filter and then incubated at 37°C for four weeks under aerobic conditions. Non-glycated albumin was obtained by incubating BSA in the same reaction mixture in the absence of glucose. At the end of the incubation period, samples were extensively dialysed against 10 mmol/L PBS (pH 7.4) at 4°C to remove unreacted glucose. Presence of AGEs was confirmed by the typical absorption and fluorescent spectra patterns of these proteins. Endotoxin content of the non-glycated (BSA) and glycated albumin (AGE) preparations (100 µg/ml) was determined by the Limulus amebocyte lysate assay and was consistently found to be lower than 6 pg/ml.
Drug treatment
Metformin was kindly supplied by Merck-Santé (Lyon, France). The drug was dissolved in pyrogen-free sterile water to produce a stock solution of 1 mg/ml, which was then filtered and stored at 4°C. Concentrations of metformin (0.1-2.5 µg/ml) used in our experiments were in the range of therapeutic plasma concentrations in diabetic patients.
Determination of cell associated adhesion molecule expression
EC surface expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin was determined by the cellular-enzyme-linked immunosorbent assay (ELISA) method. After treatment with the appropriate agents, confluent ECs were washed with PBS. To block non-specific binding, ECs were treated for 1 hour at room temperature with PBS-3% BSA. Ten µg/ml of monoclonal antibodies against ICAM-1, VCAM-1, E-selectin, and control IgG (R&D Systems) were then added to the cells for 2 hours at 37°C. After washing, ECs were incubated for 90 minutes with horseradish conjugated anti-mouse IgG (1/1000) (Bio-Rad). The peroxidase substrate, OPD, was then added to the cells. The reaction was stopped by addition of 50 µl of H 2 SO 4 (0.5 M) and the optical density was read at 490 nm.
RNA isolation and cDNA preparation
Freshly isolated human monocytes were incubated under appropriate conditions for nine days at 37°C. At the end of this incubation time, the cells were lysed with Trizol reagent, and total cellular RNA was extracted by the acid-phenol technique of Chomczynski, 21 precipitated and resuspended in diethyl pyrocarbonate water. cDNA was synthesised from RNA by incubating 2 µg of total cellular RNA with 0.1 µg oligodT (Amersham Biosciences) for 5 minutes at 98°C. The mixture was then incubated for 60 minutes at 37°C and for 10 minutes at 99°C in reverse transcription mixture (Roche Diagnostics). 
Measurement of tumour necrosis factor-alpha protein
Human monocytes were cultured for nine days in medium supplemented with 10% serum in the presence or absence of metformin. At the end of this incubation period, cells were treated with 100 ng/ml LPS for 24 hours. Levels of tumour necrosis factor-alpha (TNF-α) protein in the culture medium were measured using a double-sandwich ELISA kit (R & D Systems, Minneapolis, MN). The minimum detectable concentration of TNF-α with this assay is typically less than 4.4 pg/ml. The intra-and inter-assay coefficients of variation of this assay are less than 5.3 and 8.7%, respectively.
Western blot analysis of SR-A and LOX-1 protein
Human monocytes were cultured for nine days in medium supplemented with 10% serum in the presence or absence of metformin. At the end of this incubation period, cells were lysed in Tris buffer containing 3% sodium dodecyl sulfate (SDS), 1 mM phenyl methyl sulfonyl fluoride (PMSF), and 2% beta-mercaptoethanol. Fifteen micrograms of total cellular proteins were separated by electrophoresis through a 10% SDS-polyacrylamide gel (PAGE), and transferred to a nitrocellulose membrane using a trans blot cell system (Bio-Rad, Mississauga, ONT, Canada). The membrane was blocked for 1 hour at room temperature with PBS containing 3% BSA. After three washes with PBS/Tween 20 0.1%, the membrane was incubated overnight at 4°C with either a mouse polyclonal antibody to SR-A or a human monoclonal antibody to LOX-1 (1:1000) in PBS/Tween. The membrane was next washed with PBS/Tween and incubated for 1 hour at room temperature with a horseradish peroxidase-conjugated goat anti-mouse IgG (1:5000). Antigen detection was performed with an enhanced chemiluminescence detection system (Amersham Biosciences, Baie d'Urfe, QC, Canada). To correct for differences in protein loading, the membranes were stripped and reprobed with 1:1000 dilution of a monoclonal antibody to human beta-actin.
Quantification of cellular lipid accumulation
Freshly isolated human monocytes were incubated under appropriate conditions for nine days at 37°C. At the end of this incubation period, cells were treated with MM-LDL (100 µg/ml) for 24 hours, and cellular lipid accumulation was quantified as previously described. 22 Briefly, the cells were washed with PBS, and fixed with 10% formalin solution for 1 hour at room temperature. The cells were then washed twice with PBS and stained with 0.5% Oil Red O (Sigma). Quantification of lipid accumulation was achieved by extracting Oil Red O from stained cells with isopropanol and measuring the optical density of the extract at 510 nm.
Determination of cell viability
To evaluate a possible cellular toxicity of metformin at the maximal concentration used in the study, cell viability was determined by trypan blue exclusion. It was consistently found to be higher than 90%.
Statistical analysis
Statistical analysis of the results was performed by one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test. Differences were considered to be of statistical significance at p<0.05. Results are expressed as the mean + SEM.
Results

Effect of metformin on AGE-induced monocyte adhesion to ECs
Incubation of human umbilical venous endothelial cells (HUVECs) with AGEs (100 µg/ml) for 6 or 12 hours led to a significant increase in monocyte adhesion to endothelium. Pre-treatment of these cells with metformin (0.1-2.5 µg/ml) for 1 hour reduced AGE-induced monocyte adhesion ( figure 1A) . A similar inhibitory effect was observed when HUVECs were simultaneously exposed to metformin and AGEs or when metformin was added up to 4 hours following exposure of HUVECs to AGEs (figures 1B and 1C, respectively). The maximal inhibitory effect of metformin was observed at a concentration of 1 µg/ml. To ascertain the pathophysiological relevance of our findings, some experiments were also conducted using HAECs. To investigate whether metformin may also affect monocyte binding properties, freshly isolated human monocytes were treated with this drug prior to the addition to AGE-treated HUVECs. As shown in figure 2 , treatment of monocytes with metformin (1-2.5 µg/ml) for 1 hour at 4 or 37°C inhibited AGE-induced monocyte adhesion to HUVECs. The suppressive effect of metformin on monocyte adhesion to AGE-stimulated HUVECs was observed whether monocytes were washed or not following metformin treatment (data not shown).
Metformin inhibits AGE-induced adhesion molecule expression in HUVECs
Treatment of HUVECs with AGEs (100 µg/ml) for 6 hours resulted in a significant increase in EC expression of ICAM-1, VCAM-1 and E-selectin. Pre-incubation of the cells with increasing concentrations of metformin (0.01-2.5 µg/ml) inhibited, in a dose-dependent manner, AGE-induced expression of these cell adhesion molecules ( figure 3) . A similar suppressive effect of metformin on AGE-induced adhesion molecule expression was observed in HAECs (cell-associated adhesion molecule levels [% of control values]: ICAM-1: Control: 100+5; AGEs: 204+3; Metformin (1 µg/ml) + AGEs: 125+12; Metformin (2.5 µg/ml) + AGEs: 113+3;
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at PENNSYLVANIA STATE UNIV on February 20, 2013 dvd.sagepub.com Downloaded from VCAM-1: Control: 100+11; AGEs: 210+31; Metformin (1 µg/ml) + AGEs: 146+15; Metformin (2.5 µg/ml) + AGEs: 128+7; Eselectin: Control: 100+3; AGEs: 187+6; Metformin (1 µg/ml) + AGEs: 139+3; Metformin (2.5 µg/ml) + AGEs: 130+6).
Effect of metformin on morphological differentiation of monocytes into macrophagess
To investigate the effect of metformin on the process of human monocyte differentiation into macrophages, freshly isolated human monocytes were cultured for nine days in RPMI 1640 
Metformin decreases SR-A and LOX-1 expression during monocyte differentiation into macrophages
The effect of metformin on the process of monocyte differentiation into macrophages was further studied by investigating whether this drug may modulate the expression of SR-A and LOX-1, two specific macrophage differentiation markers. 23, 24 Culture of human monocytes for nine days in the presence of metformin (0.1-1 µg/ml) resulted in a significant decrease in SR-A and LOX-1 expression, both at the gene (figures 5A, B, and 6A, B, respectively) and protein (figures 5C and 6C, respectively) levels.
Effect of metformin on LPS-induced TNF-α production during monocyte differentiation into macrophages
Because in vitro differentiation of human monocytes to macrophages is associated with increased LPS-induced TNF-α production, 25 we next investigated the effect of metformin (0.1-1 µg/ml) on this parameter. Incubation of monocytes in the presence of 1 µg/ml metformin significantly reduced LPSstimulated TNF-α secretion (table 1) .
Effect of metformin on minimally modified lowdensity lipoprotein-induced foam cell formation
Freshly isolated human monocytes were cultured in the presence or absence of metformin for nine days and then incubated with MM-LDL for 24 hours. In the absence of metformin,
306
THE BRITISH JOURNAL OF DIABETES AND VASCULAR DISEASE 
Discussion
AGEs are associated with and may be a causal factor in the development of vascular complications in diabetes. [26] [27] [28] These products may accelerate vasculopathy in diabetes by triggering monocyte adhesion to the endothelium. 15, 16 The present study demonstrates that therapeutic concentrations of metformin inhibit AGE-induced monocyte adhesion to ECs. Given the major role of oxidative stress in AGE-induced monocyte adhesion 15, 16 and the potential antioxidant properties of metformin, 9, 10 it is tempting to speculate that this drug may inhibit this biological process through its antioxidant properties.
Monocyte adhesion to the endothelium involves the up-regulation of EC surface adhesion molecules. 29 In accordance with previous studies, [15] [16] [17] we found that AGEs induce the expression of ICAM-1, VCAM-1, and E-selectin on the surface of ECs. Our results, which demonstrate that metformin inhibits AGE-induced expression of these adhesion molecules, strongly suggest that the suppressive effect of this drug on AGE-induced monocyte adhesion may involve an inhibition of EC associated expression of these antigens. Our observations that metformin reduces to a greater extent monocyte adhesion than EC adhesion molecule expression is in agreement with those of Faruqi et al. 30 who reported enhanced effectiveness of the antioxidant, N-acetylcysteine (NAC) on monocyte adhesion as opposed to adhesion molecule expression. These results further support the notion that a threshold level of expression of adhesion molecules is required for monocyte adhesion to occur. Another interesting finding of this study is the ability of metformin to inhibit AGE-induced monocyte adhesion when added up to 4 hours after stimulation of ECs. In accordance with this observation, it has been reported that addition of NAC up to 3 hours after stimulation of ECs Evidence that short-term treatment of monocytes with metformin inhibits AGE-induced monocyte adhesion to endothelium further suggests that this drug may inhibit monocyteendothelial interaction by modifying monocyte biological properties. Because this suppressive effect is still observable at 4°C, i.e. under experimental conditions that prevent cellular uptake of the drug, 31 it is possible that metformin may alter the physical properties of the monocyte plasma membrane. Data showing that metformin affects critical biological events involved in integrin expression and monocyte adhesion, such as cell membrane polarisation and fluidity as well as Ca 2+ and Mn 2+ intracellular levels, [32] [33] [34] support this possibility. In contrast to our results, Omi et al. 35 recently reported that metformin does not inhibit high glucose-induced neutrophil adhesion to ECs. Discrepancies between these results may be related to differences in the signal transduction pathways involved in glucoseversus AGE-induced leukocyte adhesion.
Monocyte adhesion to the endothelium is followed by the migration of the cells into the subendothelial space where they differentiate into macrophages. 36 This phenomenon can be mimicked in cell culture. Our observation that metformin inhibits the morphological differentiation of cultured monocytes into macrophages suggests that this drug may favour monocyte maturation towards a cell type phenotypically and functionally different from monocyte-derived macrophages. The molecular mechanisms governing monocyte differentiation to macrophages involve a fine and complex balance of proteins and signal transduction pathways, including increased expression of integrin genes, 37, 38 and activation of transcription factors such as AP-1, STAT1 and NF-κB. [39] [40] [41] Whether metformin may inhibit this process by interfering with these events will be addressed in future studies. Differentiation of human monocytes into macrophages is associated with increased expression of a number of scavenger receptors, including SR-A and LOX-1. 23, 24 Our data demonstrate that culture of freshly isolated human monocytes with metformin results in decreased expression of SR-A and LOX-1, both at gene and protein levels.
Because the regulation of SR-A and LOX-1 expression is under redox control, [42] [43] [44] [45] one may postulate that the suppressive effect of metformin on the SR-A and LOX-1 expression may be due to its antioxidant activity. It is well known that expression of scavenger receptors plays an important role in the uptake of modified lipoproteins by vascular cells and the conversion of macrophages into foam cells. The present study demonstrates, for the first time, that metformin inhibits foam cell formation induced by MM-LDL. These results and our findings that metformin decreases the expression of SR-A and LOX-1 strongly suggest that this drug may prevent foam cell formation through its inhibitory effect on these cell surface receptors. This conclusion is further supported by the observations that vitamin E and NAC decrease the uptake of oxidised LDL and foam cell formation through inhibition of scavenger receptor expression. 45, 46 
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Conclusion
This study demonstrates that therapeutic concentrations of metformin interfere with several biological processes implicated in atherogenesis, including monocyte adhesion to ECs, monocyte differentiation into macrophages, and foam cell formation. Because monocyte adhesion to the endothelium and foam cell formation represent major events in atherogenesis, our results suggest that administration of metformin may help attenuate the progression of the atherosclerotic process in type 2 diabetic patients through inhibition of these biological events. 
